03.20.25 -- February 2025 — CDMO Opportunities And Threats Report

A properly executed virtual audit facilitates thorough qualification, condenses production timelines, enhances relationship-building, and provides early insight into a CDMO’s capability and expertise.

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage short-term needs while anticipating and planning for long-term requirements.

This research demonstrates the potential of high-pressure sterile filtration to enhance efficiency, reduce waste, and accelerate the development of innovative therapies.

Sterile fill finish operations can be complex. Those on the floor handling these products every day answer the question, "What are the top things customers should consider when beginning this step?"

See how combining Functional Design of Experiments (DOE) with traditional DOE methods enhances process optimization by capturing dynamic, time-based variations in cell culture systems.

Explore regulatory framework and expectations, and see the benefit of a comprehensive approach to CCI tailored for mAbs and complex modalities such as fusion proteins or bioconjugates.

Uncover how rapid, multidimensional assessments that optimize stability, manufacturability, and clinical success potential have been able to accelerate lead candidate selection.

The need for manufacturing support that offers adaptable, scalable solutions has become more crucial than ever for the diagnostic space.

Bob Discordia had been in stealth mode for a while. When he finally emerged, Chief Editor Louis Garguilo knew his newco would include a precise model of outsourcing. The reveal came earlier this year with the announcement he had founded EQUULUS Therapeutics, a neuroscience biotech. So how will Discordia outsource? He'll take an Uber ... and advises you do the same.

Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

Building on DNA2.0's reputation for fast, reliable DNA synthesis, we use GeneGPS® and VectorGPS® to optimize constructs for your system, from single genes to complex bispecific antibodies.

Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.

We've expanded our U.S. and Germany sites to offer end-to-end services for product development, clinical and commercial fill/finish, and ADC conjugation and purification by 2025.